Houlihan Lokey Advises FUTRUE and PharmaSGP

PharmaSGP Holding SE has increased and extended its Syndicated Loan Facility

€199,000,000

Financing Advisor

Houlihan Lokey is pleased to announce that FUTRUE GmbH (FUTRUE) has secured a €35 million bridge financing facility to support the delisting of its subsidiary, PharmaSGP Holding SE (PharmaSGP). At the same time, PharmaSGP extended its existing syndicated loan until 2030 and increased the facility by €85 million to a total of €199 million, to support the planned debt pushdown from FUTRUE and to provide additional resources under the revolving credit facility/capex facility. The transaction closed in July 2025.

FUTRUE is a holding company comprising over 20 subsidiaries and more than 90 pharmaceutical approvals. It includes some of the fastest-growing companies in the healthcare industry, known for developing transformative medicines and technologies. FUTRUE takes a unique approach in the pharmaceutical sector—lean, highly specialised, and independent—enabling the rapid development and market launch of new therapies.

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients.

Houlihan Lokey has advised on a comprehensive financing transaction comprising two key components:

  1. Bridge financing for FUTRUE
    A €35 million bridge facility was secured to support FUTRUE in initiating the planned delisting process of PharmaSGP.
  2. Extension and upsizing of PharmaSGP’s existing syndicated facility
    PharmaSGP’s existing syndicated facility was extended and significantly increased by €50 million, enhancing financial flexibility and optimising terms. Furthermore, commitments were secured to further increase the extended and upsized facility by an additional €35 million, equivalent to the bridge facility, enabling a future debt pushdown following the planned delisting.

This transaction underscores PharmaSGP’s robust capital structure and strong access to efficient financing solutions.

Houlihan Lokey acted as the exclusive financing advisor on all commercial aspects of the refinancings.

RELATED: Pharmacy, Mergers & Acquisitions